Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This pilot study will try to minimize the pain during exposure to a new red light source
(RhodoLED®, Biofrontera Bioscience GmbH, Leverkusen, Germany) used for PDT without
compromising its effect on AKs.
The study design will have an open and prospective, two-armed, split-face design.
Participants with AK lesions distributed symmetrically on the scalp, forehead, cheeks, torso,
back, arms and/or dorsal parts of the hands are eligible for inclusion. The purpose is to
investigate if a modified irradiation protocol can lower the pain while having the same
effect on AK clearance rates as compared to the standard PDT irradiation protocol.
Before any study-related procedures are performed, the participants will be thoroughly
informed about the study and will be given the opportunity to ask questions. The participants
will thereafter sign and date the informed consent form. This constitutes as visit 0.
On visit 1, a randomization to either the standard or the modified irradiation protocol will
be performed on one side of the face/body and the other irradiation protocol will then be
applied on the other side of the face/body. The participants should have AKs on two
comparable sites, i.e. two cheeks, arms or dorsal parts of the hands. One side will be
randomized to receive PDT with BF200-ALA and irradiation with the RhodoLED® lamp and the
other side will receive BF200-ALA and the Aktilite CL-128 lamp (PhotoCure ASA, Oslo, Norway),
which is the traditional lamp used at our department as mentioned above.
The treatment will be given at visit 1. During the treatment, the participants will be asked
continuously, every third minute, to estimate the pain on each treatment side using the
visual analogue scale, VAS, (where 0 is no pain and 10 is the worst pain imaginable). At the
end of the treatment, the participants will also be asked to summarize the treatment as a
whole on the VAS-scale. After visit 1, the participants will fill in a follow-up diary form
with questions regarding adverse effects (AEs) during the hours and days after the treatment.
The efficacy of the treatment will also be assessed at a follow-up (FU) visit, visit 2. The
investigators are aiming for a non-inferior analysis, i.e. the new modified irradiation
protocol should be at least as good as the standard irradiation protocol. The randomization
is blinded for the investigator at the FU visit to minimize the possibility of favoring one
irradiation protocol.